- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03145350
The Effect of a High-fat vs. High-sugar Diet on Liver Fat Accumulation and Metabolism
March 26, 2020 updated by: University of Oxford
The Effect of a High Fat Compared to a High Sugar Diet on Liver Fat Accumulation and Metabolism
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in the world.
It is currently unclear why fat starts to accumulate in the liver, although both the amount and type of food consumed have been implicated.
The majority of studies that have investigated the effects of dietary fat or sugar on liver fat have fed volunteers excess calories, which are known to increase liver fat.
The effect of specific dietary components, when consumed as part of a diet not containing excess calories, on liver fat accumulation remains unclear.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This research aims to investigate the role excessive consumption of specific macronutrients may play in the development of NAFLD.
This will be achieved by subjecting participants to two specific dietary interventions (high-fat, low-carbohydrate and low-fat, high-carbohydrate) in a randomized, crossover research design.
Liver fat content, and whole-body and hepatic fasting and postprandial lipid metabolism will be assessed before and after the specific dietary interventions.
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Oxford, United Kingdom, OX3 7LE
- Oxford Centre for Diabetes, Endocrinology and Metabolism
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participant is willing and able to give informed consent for participation in the study.
- BMI >25 <35kg/m2
- No medical condition or relevant drug therapy known to affect liver, lipid or glucose metabolism
Exclusion Criteria:
- Age <30 or >65 years
- Body mass index <25 or >35kg/m2
- A blood haemoglobin <120mg/dL
- Any metabolic condition or relevant drug therapy
- People who do not tolerate fructose
- Smoking
- History of alcoholism or a greater than recommended alcohol intake
- Pregnant or nursing mothers
- Women prescribed any contraceptive agent or device including oral contraceptives, hormone replacement therapy (HRT) or who have used these within the last 12 months
- History of severe claustrophobia
- Presence of metallic implants, pacemaker
- Haemorrhagic disorders
- Anticoagulant treatment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: High-fat, low-carbohydrate diet
Dietary intervention: Participants will consume a diet that is rich in saturated fat (20% total energy) and low in free sugars for 4 weeks.
This diet will include commonly eaten foods such as butter, cheese, and fatty meat products.
Total fat intake in this intervention will be 40-45% total energy.
|
Dietary intervention: 4 week
|
|
Active Comparator: Low-fat, high-carbohydrate diet
Dietary intervention: Participants will consume a diet that is low in saturated fat (~5% total energy) and rich in free sugars (20% total energy).The diet will include commonly eaten food and drink such as sugar sweetened beverages, confectionery (e.g.
fruit gums) and table sugar.
|
Dietary intervention: 4 week
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in liver fat content
Time Frame: Before, and within 7 days after completion of each dietary intervention
|
Investigators will measure the change in liver fat content after each of the 4 week intervention diets by magnetic resonance imaging/spectroscopy (MRI/S).
|
Before, and within 7 days after completion of each dietary intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in hepatic fatty acid partitioning
Time Frame: Within 7 days after completion of each dietary intervention
|
Investigators will utilise stable isotope tracer methodology to measure the contribution of newly synthesised fatty acids and dietary fatty acids to triglyceride production and oxidation pathways in the liver after each of the 4 week intervention diets.
|
Within 7 days after completion of each dietary intervention
|
|
Change in plasma metabolite concentrations
Time Frame: Before, and within 7 days after completion of each dietary intervention.
|
Circulating concentrations of glucose, insulin, non-esterified fatty acids, and triglycerides will be measured biochemically using a clinical analyser after each of the 4 week intervention diets.
|
Before, and within 7 days after completion of each dietary intervention.
|
|
Change in whole-body fatty acid oxidation
Time Frame: Within 7 days after completion of each dietary intervention
|
Investigators will utilise stable isotope tracer methodology to measure whole-body dietary fatty acid oxidation after each of the 4 week intervention diets.
|
Within 7 days after completion of each dietary intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Leanne Hodson, PhD, University of Oxford
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2016
Primary Completion (Actual)
December 1, 2019
Study Completion (Actual)
March 1, 2020
Study Registration Dates
First Submitted
January 9, 2017
First Submitted That Met QC Criteria
May 4, 2017
First Posted (Actual)
May 9, 2017
Study Record Updates
Last Update Posted (Actual)
March 27, 2020
Last Update Submitted That Met QC Criteria
March 26, 2020
Last Verified
May 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Oxlip-2017-HFD/HSD
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Following completion of the study, all individual data obtained from participants may potentially be shared with other researchers, both here in the United Kingdom and abroad, in appropriate circumstances.
If data is to be shared with other researchers, it will be done so under fully anonymised conditions.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NAFLD
-
Tel-Aviv Sourasky Medical CenterUnknown
-
Bambino Gesù Hospital and Research InstituteCompleted
-
The Affiliated Hospital of Hangzhou Normal UniversityRecruitingNAFLD and NASH | NAFLD( Non-alcoholic Fatty Liver Disease ) | NAFLD CirrhosisChina
-
Ziv HospitalUnknown
-
University of AthensLaikο General Hospital, AthensCompleted
-
Second Affiliated Hospital, School of Medicine,...Not yet recruitingNAFLD | Diet Habit
-
University of OxfordRecruitingNAFLD | Nutrient; ExcessUnited Kingdom
-
University of NottinghamNottingham University Hospitals NHS TrustRecruitingNAFLD | Nonalcoholic Fatty Liver Disease | Nonalcoholic Fatty Liver Disease (NAFLD) | NAFLD - Nonalcoholic Fatty Liver Disease | NAFLD (Non-alcoholic Fatty Liver Disease) | NAFLD (Nonalcoholic Fatty Liver Disease) | NAFLD - Non-Alcoholic Fatty Liver Disease | MASLD | Metabolic Dysfunction-Associated... and other conditionsUnited Kingdom
-
Enanta Pharmaceuticals, IncPharmaceutical Research AssociatesCompletedPresumptive NAFLDUnited States
-
University of California, San DiegoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Livivos...RecruitingNAFLD | NAFLD (Nonalcoholic Fatty Liver Disease) | MASLD | MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)United States
Clinical Trials on High-fat, low-carbohydrate
-
UCSF Benioff Children's Hospital OaklandNational Cattlemen's Beef AssociationCompletedHealthy | Cardiovascular Disease | Atherogenic DyslipidemiaUnited States
-
University of ArkansasCompletedDiabetes Mellitus | HypertriglyceridemiaUnited States
-
Haukeland University HospitalUniversity of BergenCompleted
-
Vårdcentralen LyckornaCompleted
-
University of Colorado, DenverKaiser PermanenteCompletedGestational Diabetes MellitusUnited States
-
Westlake UniversityCompletedPostprandial Hyperglycemia | Metabolic Disorder, GlucoseChina
-
University of NottinghamMars, Inc.Completed
-
Westlake UniversityCompletedPostprandial Hyperglycemia | Metabolic Disorder, GlucoseChina
-
Chinese Academy of SciencesCompletedHealthy and Overweight/ Obesity MalesChina
-
Liverpool John Moores UniversityLiverpool Hope UniversityCompletedCardiometabolic RiskUnited Kingdom